NCT01471106: Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer |
|
|
| Active, not recruiting | 2 | 26 | US | Dasatinib, BMS-354825, Sprycel | M.D. Anderson Cancer Center, Susan G. Komen Breast Cancer Foundation, Bristol-Myers Squibb | Breast Cancer | 01/25 | 01/25 | | |